John E Shively Selected Research

Antibodies

11/2023	Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma.
2/2022	T-cell surface generation of dual bivalent, bispecific T-cell engaging, RNA duplex cross-linked antibodies (dbBiTERs) for re-directed tumor cell lysis.
1/2021	Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
1/2021	TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody.
1/2020	Antibody Targeted PET Imaging of 64Cu-DOTA-Anti-CEA PEGylated Lipid Nanodiscs in CEA Positive Tumors.
1/2020	Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.
9/2019	Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
1/2016	Induction of antigen-specific TH 9 immunity accompanied by mast cell activation blocks tumor cell engraftment.
12/2014	CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma.
1/2014	Radioimmunoimaging of liver metastases with PET using a 64Cu-labeled CEA antibody in transgenic mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John E Shively Research Topics

Disease

76	Neoplasms (Cancer) 02/2024 - 09/2002
23	Breast Neoplasms (Breast Cancer) 02/2024 - 01/2004
10	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 12/2003
7	Neoplasm Metastasis (Metastasis) 01/2019 - 12/2003
6	Multiple Myeloma 01/2024 - 01/2013
5	Inflammation (Inflammations) 10/2023 - 01/2012
3	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 03/2005
3	Prostatic Neoplasms (Prostate Cancer) 09/2017 - 01/2013
2	Non-alcoholic Fatty Liver Disease 12/2022 - 11/2021
2	Insulin Resistance 12/2022 - 11/2021
2	Liver Neoplasms (Liver Cancer) 01/2022 - 12/2003
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 12/2004
2	Hematologic Neoplasms (Hematological Malignancy) 10/2021 - 12/2003
2	Fever (Fevers) 01/2019 - 12/2009
2	Melanoma (Melanoma, Malignant) 01/2018 - 11/2010
2	Carcinogenesis 01/2016 - 05/2011
2	Insulinoma 01/2014 - 08/2011
2	Infections 01/2013 - 10/2010
2	Carcinoma (Carcinomatosis) 09/2011 - 01/2003
1	Rectal Neoplasms (Rectal Cancer) 02/2023
1	Experimental Melanoma 01/2022
1	Obesity 01/2022
1	Hodgkin Disease (Hodgkin's Disease) 12/2021
1	Bacteremia 12/2021

Drug/Important Bio-Agent (IBA)

34	CEACAM1 ProteinIBA 01/2024 - 01/2003
20	Carcinoembryonic AntigenIBA 01/2024 - 12/2003
20	AntibodiesIBA 11/2023 - 12/2003
14	AntigensIBA 11/2023 - 12/2003
11	Proteins (Proteins, Gene)FDA Link 02/2024 - 03/2005
11	Protein Isoforms (Isoforms)IBA 01/2019 - 01/2003
9	Immunoglobulin FragmentsIBA 09/2017 - 09/2002
7	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 10/2021 - 07/2010
6	Monoclonal AntibodiesIBA 11/2023 - 05/2004
5	Cell Adhesion Molecule-1IBA 01/2024 - 12/2003
5	Radioisotopes (Radionuclides)IBA 01/2024 - 12/2003
5	CytokinesIBA 11/2023 - 12/2009
5	LipidsIBA 12/2022 - 12/2003
5	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2004
4	Cell Adhesion MoleculesIBA 01/2024 - 01/2003
4	Trastuzumab (Herceptin)FDA Link 01/2022 - 09/2005
4	Sulfhydryl Compounds (Thiols)IBA 04/2017 - 01/2008
3	Interleukin-2 (IL2)IBA 02/2024 - 01/2020
3	Glycoproteins (Glycoprotein)IBA 01/2024 - 07/2010
3	Chimeric Antigen ReceptorsIBA 10/2021 - 10/2018
3	Amino Acids FDA Link 10/2021 - 12/2003
3	Immunoglobulin G (IgG)IBA 01/2020 - 07/2010
3	human ERBB2 proteinIBA 01/2018 - 08/2010
3	LigandsIBA 04/2017 - 03/2005
2	IntegrinsIBA 02/2024 - 11/2015
2	prostaglandin D2 receptorIBA 10/2023 - 08/2023
2	Dihydrotachysterol (AT 10)IBA 12/2022 - 01/2022
2	64Cu-DOTA-trastuzumabIBA 01/2022 - 01/2018
2	Neurotensin Receptors (Neurotensin Receptor)IBA 10/2021 - 07/2014
2	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 09/2005
2	Neoplasm Antigens (Tumor Antigens)IBA 09/2019 - 01/2006
2	Lipid NanoparticlesIBA 09/2017 - 04/2017
2	Cysteine (L-Cysteine)FDA Link 04/2017 - 01/2004
2	Fluorouracil (Carac)FDA LinkGeneric 02/2015 - 12/2003
2	Exenatide (Byetta)FDA Link 01/2014 - 08/2011
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2013 - 05/2012
2	Small Interfering RNA (siRNA)IBA 08/2011 - 10/2010
2	RNA Precursors (Precursor, mRNA)IBA 05/2011 - 02/2006
2	Lysine (L-Lysine)FDA Link 04/2011 - 09/2002
2	matrigelIBA 02/2006 - 01/2003
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2005 - 01/2004
1	ProteomeIBA 02/2024
1	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 01/2024
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 11/2023
1	Coloring Agents (Dyes)IBA 11/2023
1	Oleic Acid (Oleate)IBA 12/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2022
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 12/2022
1	InterferonsIBA 12/2022
1	RNA (Ribonucleic Acid)IBA 02/2022
1	Muromonab-CD3 (Muromonab CD3)FDA Link 02/2022
1	SolutionsIBA 02/2022
1	Ado-Trastuzumab EmtansineIBA 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022
1	neurotensin (9-13)IBA 10/2021
1	NeurotensinIBA 10/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	daratumumabIBA 01/2021
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	tumor-associated antigen 72IBA 01/2020

Therapy/Procedure

27	Therapeutics 02/2024 - 12/2003
9	Radioimmunotherapy 12/2021 - 12/2003
6	Immunotherapy 01/2024 - 09/2019
5	Radiotherapy 01/2024 - 12/2003
5	Drug Therapy (Chemotherapy) 02/2015 - 12/2003
2	Neoadjuvant Therapy 02/2023 - 08/2004
2	Islets of Langerhans Transplantation 02/2013 - 08/2011
1	Transplantation 01/2022
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2022
1	Time-to-Treatment 01/2022
1	Cell Transplantation 12/2021
1	Catheters 12/2021
1	Salvage Therapy 12/2021
1	Treatment Delay 01/2021